Cantor Fitzgerald Forecasts Strong Price Appreciation for ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics (NASDAQ:ADMA) had its target price upped by equities researchers at Cantor Fitzgerald from $12.00 to $13.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Cantor Fitzgerald‘s price target indicates a potential upside of 2.12% from the stock’s current price.

Several other equities research analysts have also commented on ADMA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Mizuho set a $18.00 price objective on ADMA Biologics in a research note on Thursday. Finally, Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ADMA Biologics has an average rating of “Moderate Buy” and a consensus price target of $17.50.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded down $0.48 during midday trading on Thursday, hitting $12.73. The company’s stock had a trading volume of 4,647,407 shares, compared to its average volume of 2,703,626. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The firm has a market cap of $2.85 billion, a P/E ratio of 16.53 and a beta of 0.65. The firm’s 50 day moving average is $10.21 and its 200-day moving average is $10.88.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.20 by $0.03. The business had revenue of $141.10 million during the quarter, compared to analysts’ expectations of $138.11 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.15 EPS. Equities analysts anticipate that ADMA Biologics will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of ADMA Biologics during the 2nd quarter valued at approximately $321,037,000. Dimensional Fund Advisors LP increased its holdings in ADMA Biologics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,005,481 shares of the biotechnology company’s stock worth $45,101,000 after acquiring an additional 169,843 shares in the last quarter. Bank of America Corp DE increased its holdings in ADMA Biologics by 107.5% in the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock worth $36,019,000 after acquiring an additional 2,071,338 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in ADMA Biologics during the second quarter worth $19,753,141. Finally, Ranger Investment Management L.P. acquired a new position in ADMA Biologics during the second quarter worth $17,706,000. 75.68% of the stock is owned by institutional investors and hedge funds.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported third-quarter revenue of $141.1 million, above the roughly $138.1 million consensus, and earnings of about $0.22–$0.23 per share, ahead of estimates. Profit increased year over year, with growth in ASCENIV helping drive the results. MarketWatch article
• Positive Sentiment: The company reaffirmed its forecast for at least $530 million in 2026 revenue and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. This stronger profit outlook may support investor expectations for growth. Seeking Alpha article
• Positive Sentiment: Canaccord Genuity maintained its Buy rating. Separately, ADMA moved above its 20-day and 200-day moving averages, which technical-focused investors may view as signs of improving short- and longer-term momentum. Globe and Mail article Zacks article on moving averages
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $12 to $13 but kept a Neutral rating, suggesting the analyst sees limited near-term upside. Also, ASCENIV’s strength offset weaker Bivigam sales, leaving product performance mixed. International Business Times article

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.